PT  - JOURNAL ARTICLE
AU  - Hu, Xingsheng
AU  - Yang, Dongyong
AU  - Li, Yalun
AU  - Li, Li
AU  - Wang, Yan
AU  - Chen, Peng
AU  - Xu, Song
AU  - Pu, Xingxiang
AU  - Zhu, Wei
AU  - Deng, Pengbo
AU  - Ye, Junyi
AU  - Zhang, Hanhan
AU  - Lizaso, Analyn
AU  - Liu, Hao
AU  - Mao, Xinru
AU  - Huang, Hai
AU  - Chu, Qian
AU  - Hu, Chengping
TI  - Prevalence and clinical significance of pathogenic germline <em>BRCA1</em>/<em>2</em> mutations in Chinese non-small cell lung cancer patients
AID  - 10.20892/j.issn.2095-3941.2018.0506
DP  - 2019 Aug 01
TA  - Cancer Biology and Medicine
PG  - 556--564
VI  - 16
IP  - 3
4099  - http://www.cancerbiomed.org/content/16/3/556.short
4100  - http://www.cancerbiomed.org/content/16/3/556.full
SO  - Cancer Biol Med2019 Aug 01; 16
AB  - Objective: Germline alterations in the breast cancer susceptibility genes type 1 and 2, BRCA1 and BRCA2, predispose individuals to hereditary cancers, including breast, ovarian, prostate, pancreatic, and stomach cancers. Accumulating evidence suggests inherited genetic susceptibility to lung cancer. The present study aimed to survey the prevalence of pathogenic germline BRCA mutations (gBRCAm) and explore the potential association between gBRCAm and disease onset in Chinese advanced non-small cell lung cancer (NSCLC) patients.Methods: A total of 6,220 NSCLC patients were screened using capture-based ultra-deep targeted sequencing to identify patients harboring germline BRCA1/2 mutations.Results: Out of the 6,220 patients screened, 1.03% (64/6,220) of the patients harbored the pathogenic gBRCAm, with BRCA2 mutations being the most predominant mutations (49/64, 76.5%). Patients who developed NSCLC before 50 years of age were more likely to carry gBRCAm (P = 0.036). Among the patients harboring classic lung cancer driver mutations, those with concurrent gBRCAm were significantly younger than those harboring the wild-type gBRCA (P = 0.029). By contrast, the age of patients with or without concurrent gBRCAm was comparable to those of patients without the driver mutations (P = 0.972). In addition, we identified EGFR-mutant patients with concurrent gBRCAm who showed comparable progression-free survival but significantly longer overall survival (P = 0.002) compared to EGFR-mutant patients with wild-type germline BRCA.Conclusions: Overall, our study is the largest survey of the prevalence of pathogenic gBRCAm in advanced Chinese NSCLC patients. Results suggested a lack of association between germline BRCA status and treatment outcome of EGFR-TKI. In addition, results showed a positive correlation between pathogenic gBRCAm and an early onset of NSCLC.